Fluconazole
Diflucan, Fluconazole (fluconazole) is a small molecule pharmaceutical. Fluconazole was first approved as Diflucan on 1990-01-29. It is used to treat aids-related opportunistic infections, blastomycosis, chronic mucocutaneous candidiasis, coccidioidomycosis, and cryptococcal meningitis amongst others in the USA.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Trade Name
FDA
EMA
Diflucan, Fluconazole (discontinued: Diflucan, Fluconazole)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| ciclopirox 8% / fluconazole 1% / terbinafine hcl 1% | unapproved drug other | 2019-04-24 |
| diflucan | New Drug Application | 2025-10-10 |
| direct rx | ANDA | 2015-08-03 |
| fluconazole | ANDA | 2026-01-23 |
| fluconazole 4% / ibuprofen 2% / itraconazole 1% / terbinafine hcl 4% | unapproved drug other | 2019-04-24 |
| fluconazole in sodium chloride | ANDA | 2025-06-27 |
Indications
FDA
EMA
Show 2 more
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
D: Dermatologicals
— D01: Antifungals for dermatological use
— D01A: Antifungals for topical use
— D01AC: Imidazole and triazole derivatives, topical antifungals
— D01AC15: Fluconazole
J: Antiinfectives for systemic use
— J01: Antibacterials for systemic use
— J01R: Combinations of antibacterials
— J01RA: Combinations of antibacterials
— J01RA07: Azithromycin, fluconazole and secnidazole
— J02: Antimycotics for systemic use
— J02A: Antimycotics for systemic use
— J02AC: Triazole and tetrazole derivatives
— J02AC01: Fluconazole
HCPCS
Code | Description |
|---|---|
| J1450 | Injection fluconazole, 200 mg |
Clinical
Clinical Trials
330 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Candidiasis | D002177 | — | B37 | 5 | 14 | 23 | 12 | 16 | 68 |
| Hiv infections | D015658 | EFO_0000764 | B20 | 4 | 6 | 8 | 3 | 27 | 47 |
| Mycoses | D009181 | — | B35-B49 | 4 | 7 | 16 | 3 | 11 | 41 |
| Cryptococcal meningitis | D016919 | EFO_0007228 | B45.1 | 3 | 9 | 6 | 1 | 19 | 34 |
| Meningitis | D008581 | EFO_0000584 | G03 | 3 | 7 | 5 | 1 | 20 | 33 |
| Infections | D007239 | EFO_0000544 | — | 1 | 7 | 12 | 2 | 10 | 31 |
| Healthy volunteers/patients | — | — | — | 24 | 1 | 1 | 1 | 4 | 30 |
| Vulvovaginal candidiasis | D002181 | EFO_0007543 | B37.3 | 2 | 10 | 9 | 3 | 3 | 26 |
| Communicable diseases | D003141 | — | — | 1 | 3 | 6 | 1 | 6 | 17 |
| Oral candidiasis | D002180 | EFO_0007406 | B37.0 | 1 | 4 | 3 | 3 | 6 | 17 |
Show 41 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Myeloid leukemia acute | D015470 | — | C92.0 | 9 | 9 | 1 | — | 1 | 13 |
| Neoplasms | D009369 | — | C80 | 8 | 3 | 1 | — | 1 | 12 |
| Leukemia | D007938 | — | C95 | 5 | 5 | 2 | — | 1 | 10 |
| Stomatitis | D013280 | EFO_1001904 | K12.1 | 1 | 5 | 1 | — | — | 7 |
| Vaginitis | D014627 | EFO_0005757 | N76 | 2 | 2 | 1 | — | 1 | 6 |
| Mucositis | D052016 | EFO_1001898 | — | 1 | 4 | 1 | — | 1 | 6 |
| Hiv | D006678 | — | O98.7 | 1 | 3 | 3 | — | — | 5 |
| Precursor cell lymphoblastic leukemia-lymphoma | D054198 | — | C91.0 | 3 | 4 | 1 | — | — | 5 |
| Lymphoma | D008223 | — | C85.9 | 3 | 1 | 1 | — | — | 5 |
| Head and neck neoplasms | D006258 | — | — | 2 | 1 | 2 | — | — | 4 |
Show 45 more
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Myelodysplastic syndromes | D009190 | — | D46 | 2 | 3 | — | — | 2 | 6 |
| Vulvovaginitis | D014848 | EFO_1001240 | N76.0 | — | 4 | — | — | — | 4 |
| Myeloid leukemia | D007951 | — | C92 | 4 | 2 | — | — | — | 4 |
| Type 1 diabetes mellitus | D003922 | EFO_0001359 | E10 | 1 | 1 | — | — | 1 | 2 |
| Hematopoietic stem cell transplantation | D018380 | — | — | — | 1 | — | — | 1 | 2 |
| Kidney diseases | D007674 | EFO_0003086 | N08 | 1 | 1 | — | — | 1 | 2 |
| Sporotrichosis | D013174 | EFO_0007494 | B42 | — | 2 | — | — | — | 2 |
| Histoplasmosis | D006660 | EFO_0007310 | B39 | — | 1 | — | — | 1 | 2 |
| Myelomonocytic leukemia chronic | D015477 | — | C93.1 | — | 2 | — | — | — | 2 |
| Refractory anemia with excess of blasts | D000754 | — | D46.2 | — | 2 | — | — | — | 2 |
Show 24 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Drug interactions | D004347 | — | — | 4 | — | — | — | — | 4 |
| Prostatic neoplasms | D011471 | — | C61 | 1 | — | — | — | 2 | 3 |
| Therapeutic equivalency | D013810 | — | — | 3 | — | — | — | — | 3 |
| Graft vs host disease | D006086 | — | D89.81 | 1 | — | — | — | 1 | 2 |
| Multiple myeloma | D009101 | — | C90.0 | 1 | — | — | — | 1 | 2 |
| Large b-cell lymphoma diffuse | D016403 | — | C83.3 | 2 | — | — | — | — | 2 |
| B-cell lymphoma | D016393 | — | — | 2 | — | — | — | — | 2 |
| Brain neoplasms | D001932 | EFO_0003833 | C71 | 2 | — | — | — | — | 2 |
| Glioblastoma | D005909 | EFO_0000515 | — | 2 | — | — | — | — | 2 |
| Respiratory syncytial virus infections | D018357 | EFO_1001413 | — | 2 | — | — | — | — | 2 |
Show 21 more
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Heart failure | D006333 | EFO_0003144 | I50 | — | — | — | — | 2 | 2 |
| Drug-related side effects and adverse reactions | D064420 | — | T88.7 | — | — | — | — | 2 | 2 |
| Hematologic diseases | D006402 | EFO_0005803 | D75.9 | — | — | — | — | 2 | 2 |
| Hepatocellular carcinoma | D006528 | — | C22.0 | — | — | — | — | 1 | 1 |
| Long qt syndrome | D008133 | HP_0001657 | I45.81 | — | — | — | — | 1 | 1 |
| Delirium | D003693 | — | R41.0 | — | — | — | — | 1 | 1 |
| Torsades de pointes | D016171 | EFO_0005307 | I47.21 | — | — | — | — | 1 | 1 |
| White dot syndromes | D000080363 | — | H30.14 | — | — | — | — | 1 | 1 |
| Multifocal choroiditis | D000080364 | — | — | — | — | — | — | 1 | 1 |
| Vascular diseases | D014652 | EFO_0004264 | I77 | — | — | — | — | 1 | 1 |
Show 36 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Fluconazole |
| INN | fluconazole |
| Description | Fluconazole is a member of the class of triazoles that is propan-2-ol substituted at position 1 and 3 by 1H-1,2,4-triazol-1-yl groups and at position 2 by a 2,4-difluorophenyl group. It is an antifungal drug used for the treatment of mucosal candidiasis and for systemic infections including systemic candidiasis, coccidioidomycosis, and cryptococcosis. It has a role as a P450 inhibitor, an environmental contaminant and a xenobiotic. It is a difluorobenzene, a conazole antifungal drug, a triazole antifungal drug and a tertiary alcohol. It is functionally related to a 1,3-difluorobenzene. It derives from a hydride of a 1H-1,2,4-triazole. |
| Classification | Small molecule |
| Drug class | systemic antifungals (miconazole type) |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | OC(Cn1cncn1)(Cn1cncn1)c1ccc(F)cc1F |
Identifiers
| PDB | — |
| CAS-ID | 86386-73-4 |
| RxCUI | — |
| ChEMBL ID | CHEMBL106 |
| ChEBI ID | 46081 |
| PubChem CID | 3365 |
| DrugBank | DB00196 |
| UNII ID | 8VZV102JFY (ChemIDplus, GSRS) |
Target
No data
Variants
No data
Financial
Revenue by drug
$
€
£
â‚£
Diflucan – Pfizer
Mock data
Subscribe for the real data
Subscribe for the real data
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Estimated US medical usage
Fluconazole
Total medical expenditures per year (USD, in millions)
Mock data
Subscribe for the real data
Subscribe for the real data
Number of persons purchased
Mock data
Subscribe for the real data
Subscribe for the real data
Number of purchases
Mock data
Subscribe for the real data
Subscribe for the real data
Refill frequency
Mock data
Subscribe for the real data
Subscribe for the real data
Price per prescription (USD)
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 42,937 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
23,716 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use